Second-line therapy for refractory renal-cell carcinoma
- 31 July 2012
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 83 (1) , 112-122
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- EAU Guidelines on Renal Cell Carcinoma: The 2010 UpdateEuropean Urology, 2010
- Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the LiteratureAdvances in Urology, 2010
- Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinomaAnti-Cancer Drugs, 2010
- Sequential Sorafenib and Sunitinib for Renal Cell CarcinomaJournal of Urology, 2009
- Epidemiology of Kidney CancerAdvances in Urology, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- The changing pattern of kidney cancer incidence and mortality in EuropeBJU International, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell CarcinomaOncology, 2007
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005